TRBC1作为潜在靶点治疗T细胞来源肿瘤的研究进展  

Research progress on TRBC1 as a potential target for the treatment of T-cell tumors

作　　者：周萌 李慧 ZHOU Meng;LI Hui(Department of Hematology,Tianyou Hospital Affiliated to Wuhan University of Science and Technology,Hubei Wuhan 430000,China.)

机构地区：[1]武汉科技大学附属天佑医院血液内科,湖北武汉430000

出　　处：《现代肿瘤医学》2024年第6期1163-1166,共4页Journal of Modern Oncology

基　　金：国家自然科学基金(编号:82370196);湖北省教育厅科学研究计划中青年人才项目(编号:Q20211113);武汉市科技局知识创新专项曙光计划项目(编号:2022020801020313)。

摘　　要：T细胞来源肿瘤具有侵袭性、易耐药且预后不良的特点,常规治疗后复发率高,目前对于其的治疗不存在特效药。若能改进早期诊断和治疗手段,将有效改善患者的预后。细胞免疫治疗对B细胞来源的血液系统肿瘤获得较高的治愈率。却因为缺乏合适的靶点对治疗T细胞来源血液系统肿瘤的免疫治疗效果不佳。最新发现的T细胞受体β链恒定结构域1(TRBC1)作为一个潜在的治疗靶点,给T细胞来源肿瘤的诊断和治疗带来希望。本文将对TRBC1在当前的疾病诊断和细胞免疫治疗中研究进展进行综述。T-cell tumors are aggressive,easily resistant and have a poor prognosis,and the recurrence rate is high after conventional treatment,and there are currently no specific drugs for their treatment.If early diagnosis and treatment methods can be improved,it will effectively improve the prognosis of patients.Cellular immunotherapy achieves a high cure rate for B-cell-derived hematologic tumors.However,due to the lack of suitable targets,immunotherapy for the treatment of T cell-derived hematologic tumors is not effective.The newly discovered TRBC1 as a potential therapeutic target brings hope for the diagnosis and treatment of T-cell tumors.This article will review the current research progress of TRBC1 in disease diagnosis and cellular immunotherapy.

关 键 词：T细胞抗原受体 T细胞受体β链恒定结构域1 血液肿瘤诊断 CAR-T细胞治疗 T细胞活化信号转导 

分 类 号：R730.51[医药卫生—肿瘤]